The Technical Analyst
Champions Oncology Inc [CSBR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Champions Oncology Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.95% $4.60
America/New_York / 8 mai 2024 @ 15:14
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 62.53 mill |
| EPS: | -0.720 |
| P/E: | -6.39 |
| Earnings Date: | Jul 22, 2024 |
| SharesOutstanding: | 13.59 mill |
| Avg Daily Volume: | 0.0037 mill |
| RATING 2024-05-08 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.39 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.09x |
| Company: PE -6.39 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.842 (-59.95%) $-2.76 |
| Date: 2024-05-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.38 - 4.82 ( +/- 4.78%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-10-09 | Davis Brady | Buy | 68 000 | Option to purchase Common Stock |
| 2023-10-09 | Davis Brady | Buy | 7 500 | Option to purchase Common Stock |
| 2023-10-09 | Davis Brady | Buy | 135 000 | Option to purchase Common Stock |
| 2024-01-12 | Mendelson Daniel Newman | Buy | 1 000 | Common Stock |
| 2024-01-11 | Mendelson Daniel Newman | Buy | 2 000 | Common Stock |
| INSIDER POWER |
|---|
| 89.09 |
| Last 100 transactions |
| Buy: 1 237 465 | Sell: 480 213 |
Forecast:
16:00 - $4.86
Live Trading Signals (every 1 min)
Forecast
1: 15:55 - $4.76
Forecast 2: 16:00 - $4.86
Forecast 3: 16:00 - $4.86
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $4.60 (-2.95% ) |
| Volume | 0.0020 mill |
| Avg. Vol. | 0.0037 mill |
| % of Avg. Vol | 54.56 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CSBR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CSBR
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Latest Press Releases
2024-03-12 16:30:00 - Press Release
Champions Oncology Reports Quarterly Revenue Of $12.0 Million
Hackensack, nj / accesswire / march 12, 2024 / champions oncology, inc. (nasdaq:csbr), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2024, ended january 31, 2024. third quarter and recent highlights: third quarter revenue of $12.0 million, a decline of 6% gross margin declined to 35% college of american pathologists (cap) has awarded accreditation to us-based laboratory ronnie morris, ceo of champions, commented, "as discussed over the course of the year, we're navigating through a challenging economic environment, specifically in the biotech sector, that began approximately one year ago.
2024-03-07 09:00:00 - Press Release
Champions Oncology's Us Laboratory Has Acquired Distinguished Cap Accreditation
Hackensack, nj / accesswire / march 7, 2024 / champions oncology, inc. (nasdaq:csbr), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced that the college of american pathologists (cap) has awarded accreditation to its us-based laboratory. this achievement of cap accreditation continues to strengthen champions oncology's reputation as a high-quality, state of the art laboratory providing the highest standards of excellence in histology and immunohistochemistry services.
2024-03-06 16:35:00 - Press Release
Champions Oncology To Announce Third Quarter Financial Results On Tuesday, March 12, 2024
Hackensack, nj / accesswire / march 6, 2024 / champions oncology, inc. (csbr), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended january 31, 2024, on tuesday, march 12, 2024, after market close. the company will host a conference call to discuss the results that day at 4:30 p.m.
2023-12-12 16:00:00 - Press Release
Champions Oncology Reports Quarterly Revenue Of $11.6 Million
Hackensack, nj / accesswire / december 12, 2023 / champions oncology, inc. (nasdaq:csbr), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2024, ended october 31, 2023. second quarter and recent highlights: second quarter revenue of $11.6 million, a decline of 19% revised fiscal year 2024 revenue guidance to be generally in-line with last year's results strong quarterly bookings european lab received iso accreditation and ats certification hired brady davis as president to develop new strategic initiatives ronnie morris, ceo of champions, commented, "as discussed during our first quarter earnings call, we're navigating through a challenging economic environment, specifically in the biotech sector, that began approximately one year ago.
2023-12-04 16:30:00 - Press Release
Champions Oncology To Announce Second Quarter Financial Results On Tuesday, December 12, 2023
Hackensack, nj / accesswire / december 4, 2023 / champions oncology, inc. (csbr), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended october 31, 2023, on tuesday, december 12, 2023, after market close. the company will host a conference call to discuss the results that day at 4:30 p.m.
Latest News
2024-03-06 16:35:00 - Accesswire
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024
HACKENSACK, NJ / ACCESSWIRE / March 6, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2024, on Tuesday, March 12, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
2023-12-12 17:54:09 - Seeking Alpha
Champions Oncology, Inc. (CSBR) Q2 2024 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q2 2024 Earnings Conference Call December 12, 2023 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Operator Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2024 Earnings Call.
2023-12-04 16:30:00 - Accesswire
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023
HACKENSACK, NJ / ACCESSWIRE / December 4, 2023 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2023, on Tuesday, December 12, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
2023-07-20 16:00:00 - Accesswire
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 24, 2023
HACKENSACK, NJ / ACCESSWIRE / July 20, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter and year ended April 30, 2023, on Monday, July 24, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
2023-03-15 18:19:03 - Zacks Investment Research
Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates
Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200% and 2.26%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
2023-03-13 08:30:00 - Accesswire
Champions Oncology to Announce Third Quarter Financial Results on Wednesday, March 15, 2023
HACKENSACK, NJ / ACCESSWIRE / March 13, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2023, on Wednesday, March 15, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
2023-01-29 00:37:56 - Seeking Alpha
Champions Oncology Trades At A Sufficient Discount To R&D Capacity
CSBR runs a PDX bank. PDXs are mice models of human derived tumors. The company offers services to bio and pharma companies in pre clinical treatment testing. Its test have high predictive power for human results, without the associated cost.
2022-12-13 20:54:06 - Seeking Alpha
Champions Oncology, Inc. (CSBR) Q2 2023 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q2 2023 Results Conference Call December 13, 2022 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Scott Henry - ROTH Capital Operator Good day, ladies and gentlemen, and welcome to the Champions Oncology Second Quarter Fiscal Year 2023 Earnings Call. At this time, all participants have been placed on a listen-only mode and the floor will be opened for you questions and comments after the presentation.
2022-12-09 16:30:00 - Accesswire
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022
HACKENSACK, NJ / ACCESSWIRE / December 9, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the second quarter ended October 31, 2022, on Tuesday, December 13, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
2022-09-09 16:41:05 - Seeking Alpha
Champions Oncology, Inc. (CSBR) Q1 2023 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2023 Earnings Conference Call September 8, 2022 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen, and welcome to the First Quarter Fiscal Year 2023 Champions Oncology Conference Call [Operator Instructions]. It is now my pleasure to turn the floor over to your host, Ronnie Morris, CEO of Champions Oncology.